Overview

CorTec is a Freiburg-based commercial BCI developer, established in 2010 with a focus on clinical translation and wireless implant technology. The company advanced beyond pure research to pursue commercial neuroinformatics and neural device development, positioning itself as a European counterpoint to US-based competitors.

Brain Interchange System

The Brain Interchange system is a fully wireless, implantable closed-loop neurostimulation device used both to record cortical signals for decoding and to deliver targeted stimulation. FDA has granted it two Breakthrough Device Designations: stroke motor rehabilitation (April 2026) and computer cursor control for people with non-progressive quadriplegia (announced 31 August 2026). The absence of percutaneous connectors reduces infection risk and facilitates longer-term implantation without repeated surgical intervention.

Clinical Milestone

CorTec implanted the first patient in its US stroke-rehabilitation trial in July 2025 at Harborview Medical Center in Seattle, demonstrating successful technology transfer from Germany to the United States healthcare system. This milestone establishes CorTec as a viable international competitor with FDA regulatory engagement.

Therapeutic Focus

The company is pursuing NIH-funded stroke rehabilitation trials, targeting restoration of motor function in stroke patients through targeted brain stimulation guided by neural recordings. This application differs from communication BCIs, addressing a larger patient population with significant unmet clinical needs. CorTec joined the FDA Total Product Life Cycle Advisory Program (TAP) for the stroke programme on 23 April 2026, and three patients had been implanted in the University of Washington IDE study by August 2026.

Market Position

CorTec demonstrates strong European neurotechnology expertise and establishes alternative technology pathways to the dominant US-based approaches.